CME LIVE OPEN ACCESS

Journal of Cancer Research

Research Article ISSN: 2578-3726

Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis

Alexandre Tavartkiladze[1,2,3*], Gaiane Simonia[1,2], Ruite Lou[3], Pati Revazishvili[1,2], Dinara Kasradze[2,4], Maia Maisuradze[2], Nana Okrostvaridze[2] and Levan Tavartkiladze[1,2]

[1]*Tbilisi State Medical University, Tbilisi, Georgia.*

[2]*Institute for Personalized Medicine., Tbilisi, Georgia.*

[3]*Department of Biotechnology, Foconsci Chemical Industry., Shandong, China.*

[4]*David Tvildiani Medical University, Tbilisi, Georgia.*

Corresponding Author: Alexandre Tavartkiladze, Institute for Personalized Medicine Tbilisi State Medical University, Georgia.

Received: 2024 Nov 07 **Accepted:** 2024 Nov 26 **Published:** 2024 Dec 06

Abstract

Cancer remains one of the leading causes of mortality worldwide, with traditional treatments often facing significant challenges in terms of efficacy, resistance, and toxicity. As cancers progress to advanced stages, they frequently develop resistance to monotherapies, underscoring the need for multi-targeted treatments that can address the complexity of tumor biology. AminoSineTriComplex, a formulation of bioactive compounds derived from various medicinal plants, represents a promising multi-targeted approach to oncological therapy. This study explores the effects of AminoSineTriComplex across several carcinogen-induced rat models of breast, colon, and prostate cancers, with a focus on its mechanisms, pathway-specific actions, and potential efficacy in diverse cancer types.

The composition of AminoSineTriComplex includes Epigallocatechin Gallate (EGCG), Resveratrol, Quercetin, Genistein, Berberine, Sulforaphane, Apigenin, Luteolin, Honokiol, and Thymoquinone, each derived from well-known medicinal plants. These compounds target a wide array of cancer-related pathways, including PI3K/AKT/mTOR, NF-κB, VEGF, Wnt/β-Catenin, JAK/STAT, Hedgehog, Notch, and DNA damage repair mechanisms. This multi-pathway inhibition allows AminoSineTriComplex to reduce cancer cell proliferation, induce apoptosis, limit angiogenesis, and suppress the invasive and metastatic potential of tumors. Through these effects, AminoSineTriComplex offers a comprehensive approach to disrupting cancer growth at multiple levels, a strategy that is particularly valuable in cancers prone to resistance.

In breast cancer models, AminoSineTriComplex demonstrated significant tumor stabilization, with some models achieving partial or complete remission, particularly in hormone-sensitive and early-stage cases. Similarly, in prostate cancer models, including both hormone-sensitive and androgen-insensitive types, AminoSineTriComplex showed high rates of remission and stabilization, pointing to its potential as a standalone or adjunctive therapy in prostate cancer management. Colon cancer models displayed a range of responses, with early-stage adenocarcinomas showing promising remission rates, while more aggressive and resistant colon tumors presented challenges that indicate the need for combinatory therapies.

Potential applications of AminoSineTriComplex extend to brain cancers, particularly glioblastoma multiforme (GBM), where PI3K/AKT, NF-κB, and VEGF pathways are central to tumor progression. Some components of AminoSineTriComplex, such as EGCG and Resveratrol, have demonstrated a capacity to cross the blood-brain barrier, suggesting potential for application in brain tumors, especially when paired with delivery systems designed to optimize bioavailability in the brain. Although preclinical evidence on brain cancer efficacy is limited, the compound's multi-pathway targeting aligns with the therapeutic needs of aggressive brain cancers.

AminoSineTriComplex's low toxicity profile, as observed in preclinical studies, enhances its suitability for integrative and long-term use. Unlike conventional chemotherapies that often induce significant side effects, AminoSineTriComplex's plant-based bioactive compounds demonstrate a relatively high therapeutic index, allowing for sustained administration with minimal adverse effects. This safety profile positions AminoSineTriComplex as a potential maintenance therapy to manage disease progression in advanced cancer patients, as well as a candidate for combination with conventional therapies to potentially

reduce the required doses and thus alleviate toxic side effects.

The findings of this study suggest that AminoSineTriComplex could serve as a valuable addition to oncological treatment strategies, addressing multiple cancer types and stages through a holistic approach. Future clinical studies will be necessary to validate these preclinical outcomes in human populations, optimize dosing strategies, and investigate the full therapeutic scope of AminoSineTriComplex in various cancers. With its broad-spectrum targeting and low toxicity, AminoSineTriComplex could redefine integrative cancer therapy, offering patients a safer and more comprehensive treatment option that aligns with the growing demand for holistic and sustainable cancer care solutions.

Keywords: AminoSineTriComplex, Multi-Targeted Cancer Therapy, Bioactive Compounds, Pi3k/Akt/Mtor Pathway, Nf-Kb Pathway, Vegf Inhibition, Cancer Resistance, Tumor Stabilization, Plant-Based Anticancer Agents, Integrative Oncology, Breast Cancer, Prostate Cancer, Colon Cancer, Glioblastoma, Angiogenesis, Apoptosis, Therapeutic Resistance, Translational Medicine

1. Introduction

Cancer remains a significant global health burden, presenting complex challenges in therapeutic intervention, especially in advanced stages where conventional treatment approaches often encounter resistance. According to the World Health Organization (WHO), cancer accounts for approximately 10 million deaths annually, with the most common cases being lung, breast, colon, prostate, and stomach cancers. Despite the development of numerous chemotherapeutic agents, targeted therapies, and immunotherapies, treatment resistance continues to be a formidable barrier, particularly in cancers at metastatic or late stages. This persistence in resistance underlines the necessity for innovative therapeutic strategies that leverage multi-targeted approaches to disrupt cancer growth, survival, and spread comprehensively.

AminoSineTriComplex, a formulation of plant-derived bioactive molecules, represents an emerging therapeutic paradigm for managing various cancer types. This novel compound amalgamates bioactive substances extracted from the decomposition of plants known for their anti-cancer properties, including chamomile, Camellia sinensis (green tea), grapes, Glycine max (soybeans), Berberis vulgaris (barberry), thyme, Magnolia officinalis, and Nigella sativa (black cumin). The primary bioactive compounds—Epigallocatechin Gallate (EGCG), Resveratrol, Quercetin, Genistein, Berberine, Sulforaphane, Apigenin, Luteolin, Honokiol, and Thymoquinone—each exhibit unique anti-cancer effects, targeting different cellular pathways implicated in cancer progression. The careful combination of these agents in AminoSineTriComplex provides a synergistic effect, enhancing bioavailability and potency to establish a potent anti-tumor and preventative solution. This study aims to evaluate the efficacy of AminoSineTriComplex in rat models of chemically induced breast, colon, and prostate cancers. By monitoring blood biomarker dynamics, tumor remission rates, and progression markers, we hope to gain insights into its potential to modulate key molecular pathways involved in tumorigenesis. Such an approach aligns with the current trend in oncological research, which seeks to target not just cancer cells themselves but also the molecular and biochemical environments that foster their growth and resistance.

1.1. Pathways of Interest in Cancer Therapy and Their Therapeutic Targeting with AminoSineTriComplex

The evolution of cancer therapies has shifted towards precision and multi-targeted approaches, aimed at disrupting key pathways that drive cancer cell proliferation, survival, invasion, and immune evasion. AminoSineTriComplex's multi-targeted approach makes it particularly promising in this regard, as it interferes with multiple pathways simultaneously, reducing the likelihood of resistance through redundancy in cancer cell signaling. Here, we outline the pathways of interest in cancer biology and their relevance to the activity of AminoSineTriComplex.

PI3K/AKT/mTOR Pathway

The PI3K/AKT/mTOR pathway plays a central role in cell growth, metabolism, and survival. Aberrant activation of this pathway, through genetic mutations or receptor overexpression, is commonly observed in various cancers, promoting tumor growth and resistance to apoptosis. Targeting this pathway, particularly with mTOR inhibitors, has shown potential in curbing tumor progression. EGCG and Resveratrol in AminoSineTriComplex are known to inhibit this pathway, disrupting metabolic functions essential for tumor growth and survival.

- **RAS/RAF/MEK/ERK Pathway (MAPK Pathway)**

Also known as the MAPK pathway, this signaling cascade is crucial for cell proliferation and survival, with mutations in genes like KRAS and BRAF leading to continuous activation in cancers such as melanoma. AminoSineTriComplex components such as Genistein and Quercetin have shown efficacy in downregulating MAPK signaling, decreasing cancer cell proliferation, and enhancing apoptosis in susceptible cancer types.

- **Wnt/β-Catenin Pathway**

This pathway regulates cell fate, migration, and proliferation and is often aberrantly activated in cancers, contributing to cancer stem cell survival and metastatic potential. Inhibition of this pathway can prevent cancer cell self-renewal and reduce tumor recurrence. Resveratrol, a key component of AminoSineTriComplex, interferes with Wnt/β-catenin signaling, thereby targeting cancer stem cells and reducing the risk of metastasis and relapse.

- **JAK/STAT Pathway**

Critical in cytokine signaling, the JAK/STAT pathway is frequently activated in cancers, particularly those

characterized by high levels of immune evasion and chronic inflammation. AminoSineTriComplex components, notably Sulforaphane and Thymoquinone, inhibit JAK/STAT signaling, thereby reducing cancer cell proliferation and diminishing immune evasion mechanisms, especially beneficial in hematologic malignancies.

- **Hedgehog Pathway**

Important in cancer stem cell maintenance, the Hedgehog pathway is implicated in the initiation and maintenance of tumors with high stem cell characteristics, such as basal cell carcinoma. By targeting this pathway, Honokiol in AminoSineTriComplex suppresses cancer stem cell renewal and tumor growth, aligning with the therapy's multi-targeted approach against cancer initiation and progression.

- **Notch Pathway**

Dysregulation of the Notch pathway is linked to cancer progression and the maintenance of cancer stem cells. This pathway's inhibition can reduce metastasis and tumor progression. AminoSineTriComplex, with bioactives like Apigenin, targets the Notch pathway, impeding cancer stem cell sustainability and reducing the tumor's ability to metastasize.

- **DNA Damage Repair Pathways (e.g., PARP, BRCA)**

Cancers with defective DNA repair mechanisms, particularly in homologous recombination repair, often rely on alternative repair pathways to survive. Targeting DNA repair proteins, such as with PARP inhibitors, can exploit cancer cells' inability to repair DNA damage, leading to cell death. Resveratrol and Quercetin in AminoSineTriComplex may complement these therapies by enhancing DNA damage and impairing repair mechanisms, particularly relevant for BRCA-mutated cancers.

- **Immune Checkpoint Pathways (e.g., PD-1/PD-L1, CTLA-4)**

Tumors often escape immune detection by activating immune checkpoint pathways, which inhibit immune responses against them. By reinvigorating the immune system, AminoSineTriComplex components such as Thymoquinone and Berberine hold potential to enhance immune-mediated tumor suppression, especially in immunogenic cancers.

- **NF-κB Pathway**

A transcription factor involved in inflammation, cell survival, and proliferation, NF-κB's persistent activation is associated with cancer progression and metastasis. AminoSineTriComplex bioactives, including Sulforaphane and EGCG, inhibit NF-κB signaling, reducing inflammation-driven tumor progression and making cancer cells more susceptible to apoptosis.

- **VEGF Pathway (Angiogenesis)**

VEGF signaling promotes angiogenesis, providing tumors with nutrients and oxygen essential for growth and spread. By inhibiting VEGF, as achieved with Quercetin and Luteolin, AminoSineTriComplex can effectively "starve" the tumor by curbing its blood supply, particularly beneficial in solid tumors.

- **-MYC Pathway**

c-MYC is a potent oncogene regulating the cell cycle, metabolism, and apoptosis. Its overexpression is associated with aggressive tumor progression. While direct targeting of c-MYC is complex, AminoSineTriComplex indirectly inhibits this pathway's downstream targets, reducing metabolic flexibility in cancer cells and curbing tumor growth.

- **TGF-β Pathway**

TGF-β signaling plays a dual role in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. In advanced cancers, inhibiting TGF-β can reduce metastasis and improve immune response, which is where Apigenin and Genistein in AminoSineTriComplex are effective.

1.1. In tegration of Pathway Inhibitors and Natural Bioactives

The concept of multi-targeting through natural bioactives is exemplified in the composition of AminoSineTriComplex. The selected molecules not only target individual cancer pathways but also work synergistically to suppress multiple aspects of tumor biology, from proliferation and angiogenesis to immune evasion and metastasis. For instance, the combination of EGCG, Resveratrol, and Quercetin provides complementary effects on pathways such as PI3K/AKT/mTOR and NF-κB, addressing both growth signaling and inflammation. Likewise, the inclusion of Genistein and Berberine targets JAK/STAT and MAPK, ensuring a robust response against immune evasion and metastatic spread.

Moreover, these compounds boast relatively low toxicity profiles, as indicated by their LD_{50} values in rodent studies. For example, EGCG from green tea has an LD_{50} of approximately 2000 mg/kg, signifying safety at commonly consumed doses. This feature, combined with their multi-targeted actions, makes the bioactives in AminoSineTriComplex especially promising as complementary agents in cancer prevention and management. In this study, we investigate the efficacy of AminoSineTriComplex in carcinogen-induced rat models of breast, colon, and prostate cancers, focusing on biomarker dynamics and therapeutic outcomes. The inclusion of these natural bioactive molecules is intended to modulate pathway-specific activities, potentially leading to improved tumor control, remission, and quality of life outcomes. By examining these effects in animal models, this study aims to contribute insights into the use of plant-based complexes as adjuncts or alternatives to conventional therapies, particularly in resistant and advanced-stage cancers.

1.3. Aim and Scope of the Study

This study aims to elucidate the antitumor properties of AminoSineTriComplex by examining blood biomarkers that indicate therapeutic response, such as cytokine levels, tumor necrosis markers, and angiogenic factors. Additionally,

Citation: Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis. *J Cancer Res, 2*(1), 1-18.

tumor remission rates, progression markers, and histological analyses will provide further insights into the complex's efficacy. We hypothesize that AminoSineTriComplex will exert significant anti-tumor activity by modulating multiple signaling pathways, leading to reduced tumor progression and enhanced remission. The use of carcinogen-induced rat models for breast, colon, and prostate cancers allows for the evaluation of this complex across various cancer types, providing a broader understanding of its therapeutic potential. By targeting multiple pathways simultaneously, AminoSineTriComplex aims to circumvent the issue of therapeutic resistance, presenting a promising multimodal approach in the ongoing battle against cancer.

In conclusion, AminoSineTriComplex is posited as a unique plant-based compound with the potential to revolutionize cancer treatment by addressing multiple facets of tumor biology. This study's findings may pave the way for novel therapeutic strategies that integrate natural compounds to enhance traditional cancer therapies or serve as alternatives in resistant cases. Through detailed biomarker and pathway analyses, we aim to establish AminoSineTriComplex as a viable option in the realm of multi-targeted cancer treatment.

2. Materials and Methods

2.1. Study Design

This study was meticulously designed to explore the therapeutic efficacy of AminoSineTriComplex, a multi-targeted plant-based bioactive compound, in carcinogen-induced rat models of breast, colon, and prostate cancers. The study utilized a robust experimental model to simulate real-world clinical conditions, examining both the tumor-specific therapeutic response and overall health impacts through biomarker analysis and detailed histological evaluations.

2.2. Subjects and Grouping

The subjects included a total of 400 healthy white rats, selectively divided based on tumor type for comprehensive analysis across multiple cancer models. The rats were grouped as follows:

- **Breast Cancer Group:** Consisting of 150 rats, this group was divided into three subgroups of 50 rats each, representing distinct types of breast tumors.
- **Colon Cancer Group:** Another 150 rats were assigned to three subgroups of 50 rats each, with each subgroup dedicated to a different type of colon cancer model.
- **Prostate Cancer Group:** Similarly, 150 rats were split into three subgroups, each containing 50 rats and representing different prostate cancer models.
- **Control Group:** A separate group of 100 healthy white rats served as a control. These rats were monitored under identical conditions, but no carcinogens were introduced to induce tumors.

Each rat in the experimental groups was carefully monitored for tumor development, progression, and response to treatment.

2.3. Tumor Induction and Models

Three primary cancer types were induced in this study—breast, colon, and prostate cancers. Each cancer type involved different rat models to reflect the diversity of tumor biology and enhance the study's applicability.

1. Breast Cancer Models:

- **DMBA-Induced Mammary Tumors:** 50 rats were subjected to the chemical 7,12-dimethylbenz[a] anthracene (DMBA) to induce mammary tumors. DMBA is a well-established carcinogen known for mimicking the molecular pathology of human breast cancer.
- **R3230AC Mammary Adenocarcinoma:** Another 50 rats were implanted with R3230AC cells to develop a mammary adenocarcinoma model.
- **MTLn3 Metastatic Mammary Adenocarcinoma:** The final 50 rats in this group were injected with MTLn3 cells, which form highly metastatic mammary tumors.

2. Colon Cancer Models:

- **DHD/K12/TRb (DMH-Induced Colon Adenocarcinoma):** 50 rats received 1,2-dimethylhydrazine (DMH), a potent carcinogen for colon cancer induction, forming the DHD/K12/TRb tumor model.
- **PROb Metastatic Colorectal Cancer:** 50 rats were injected with PROb cells, generating a model that reflects metastatic colorectal cancer.
- **Ward Colon Tumor:** The remaining 50 rats were implanted with Ward colon tumor cells, developing colon tumors with distinct biological characteristics.

3. Prostate Cancer Models:

- **Dunning R-3327 (Sublines H, AT1, MAT-Lu):** Dunning R-3327 cells were introduced into 50 rats, creating three prostate cancer sublines (H, AT1, and MAT-Lu) with varying aggression and metastatic potential.
- **PA-III:** Another 50 rats were injected with PA-III cells, a model that represents an advanced form of prostate cancer.
- **LNCaP-R:** The last 50 rats in this group were inoculated with LNCaP-R cells, a model of hormone-resistant prostate cancer.

2.4. Each Model was Validated to Ensure the Reliability and Reproducibility of Results.

Intervention Protocol

AminoSineTriComplex was administered to the rats in each cancer group at a daily dose of 75 mg/kg. The treatment was initiated seven days after tumor induction and continued for a period of seven weeks. This dosage was selected based on preliminary toxicity studies, which confirmed its safety and potential efficacy across cancer types without causing adverse effects. Control rats did not receive AminoSineTriComplex to assess its impact solely on the cancer-induced subjects. To ensure optimal bioavailability and targeted delivery of AminoSineTriComplex, each compound is encapsulated in 1000 mg capsules formulated with a gut-resistant, enteric-soluble coating. This design mitigates early degradation in the gastrointestinal tract and enhances the compounds' absorption and intracellular penetration. For this study, a

dosing regimen was implemented in which subjects received a daily dose of 4 to 12 capsules (4,000 to 12,000 mg) over a 45-day period.

The molecular activation method refers to a process by which bioactive compounds are chemically or structurally modified to enhance their stability, bioavailability, and cellular uptake. This approach involves altering the compound's polarity, solubility, and functional groups to improve its interaction with cell membranes, thereby facilitating more efficient transport across the cell barrier. Through such modifications, the bioactive agents are better absorbed and retained within target cells, maximizing their therapeutic effects at lower doses and minimizing systemic degradation and excretion. The capsules contain highly active antioxidant, cytostatic, and immunomodulatory compounds. Furthermore, a unique dosage protocol and molecular activation method were employed to maximize absorption efficiency and the bioactive compounds' intracellular delivery. This specialized approach aligns with the therapeutic objectives of AminoSineTriComplex, enhancing its capacity to modulate key oncogenic pathways while minimizing systemic toxicity.

2.5. Biomarker Monitoring

The study employed a rigorous biomarker monitoring protocol to evaluate the impact of AminoSineTriComplex on specific blood markers associated with each cancer type. Blood samples were collected every two weeks to track dynamic changes in key biomarkers, including tumor-specific antigens, angiogenic factors, and inflammatory markers. The blood was collected via tail vein puncture under sterile conditions, and the samples were processed for plasma separation and analysis.

- **Breast Cancer Markers:**
- **CA 15-3:** Commonly elevated in breast cancer, CA 15-3 was measured as an indicator of tumor load.
- **CEA (Carcinoembryonic Antigen):** CEA was monitored as a general cancer marker, given its role in multiple cancer types, including breast cancer.
- **Prolactin:** This hormone was assessed due to its involvement in breast tissue growth and potential relevance to breast cancer progression.
- **VEGF (Vascular Endothelial Growth Factor):** VEGF levels were recorded to evaluate angiogenesis, a critical factor in tumor growth and metastasis.

- **Colon Cancer Markers:**
- **CEA:** CEA was measured as a primary biomarker for colon cancer.
- **CA 19-9:** Elevated in several gastrointestinal cancers, CA 19-9 was tracked as a supplementary marker for colon cancer.
- **VEGF:** As in the breast cancer group, VEGF levels were monitored to assess angiogenic activity and tumor progression in colon cancer.

- **Prostate Cancer Markers:**
- **PSA (Prostate-Specific Antigen):** PSA is a prostate cancer-specific marker, and its levels were monitored to gauge tumor response to treatment.
- **VEGF:** VEGF was similarly tracked to evaluate angiogenesis in prostate cancer.

Each biomarker was quantified using ELISA (Enzyme-Linked Immunosorbent Assay) kits specific to rat serum to ensure accuracy and specificity in measurements.

2.6. Tumor Size and Response Assessment

Tumor progression and response to AminoSineTriComplex were assessed through ultrasonographic measurements performed biweekly. Tumor volume was calculated using standard methods to determine any reductions in size. Responses were categorized as follows:

- **Complete Remission:** No detectable tumor observed on ultrasonography.
- **Partial Response:** Tumor volume reduced by more than 30%.
- **Stable Disease:** Less than 30% reduction or 20% increase in tumor volume.
- **Progressive Disease:** Tumor volume increased by more than 20%.

Control Group Monitoring: The control group was monitored under identical conditions, with blood biomarkers measured at the same intervals. This group served as a baseline to observe normal physiological changes and ensure that any observed therapeutic effects were attributable to AminoSineTriComplex rather than external variables.

2.7. Histological Examination and Pathway Analysis

At the end of the study, all rats were euthanized humanely, and tumors, along with other relevant tissues, were collected for histological and molecular analysis. Histological staining techniques, including hematoxylin and eosin (H E) staining, were used to evaluate the cellular and structural characteristics of the tumors. Immunohistochemical analyses were also performed to investigate the expression of specific pathway proteins affected by AminoSineTriComplex, such as PI3K/AKT, NF-κB, and VEGF.

2.8. Statistical Analysis

The study employed a rigorous statistical analysis plan to ensure reliable and interpretable results. Descriptive statistics were used to summarize baseline characteristics of the rats, tumor volumes, and biomarker levels. Changes in biomarkers over time were analyzed using repeated-measures ANOVA, with post hoc testing to compare differences between treated and control groups. Kaplan-Meier survival analysis was performed to assess overall survival and tumor-free survival rates in each group, and p-values < 0.05 were considered statistically significant.

2.9. Ethical Considerations

The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) in compliance with national and international guidelines for animal welfare. All experimental procedures were conducted following ethical standards, with efforts to minimize discomfort and ensure humane treatment of the animals throughout the study.

Figure #1
Below is a summary graph chart for the Materials and Methods section of the AminoSineTriComplex study. The chart illustrates key components such as the number of study subjects, tumor models, intervention dosage, types of biomarkers monitored, tumor response categories, control group monitoring, histological examinations, and statistical analyses used in the study. This provides a visual overview of the setup and procedures involved in evaluating AminoSineTriComplex's effects on cancer progression.



3. Results

This study evaluated the efficacy of AminoSineTriComplex in multiple carcinogen-induced cancer models in rats, encompassing breast, colon, and prostate tumors. By systematically assessing tumor response rates, including complete remission, partial response, stabilization, and progression, we aimed to delineate the therapeutic impact of AminoSineTriComplex across distinct tumor types. Tumor response outcomes were monitored at set intervals using blood biomarkers and ultrasound imaging, providing quantitative measures of treatment efficacy. Here, we present a detailed breakdown of the results for each tumor type and model used in this study.

3.1. DMBA-Induced Mammary Tumors

The DMBA-induced mammary tumor model in rats serves as an analog for studying breast cancer, as it mimics the pathology observed in human breast cancers. This group exhibited varying responses to AminoSineTriComplex treatment, showcasing notable results across different response categories:

- **Complete Remission:** Out of 50 rats in this model, 15 achieved complete remission, representing 30% of the sample. These rats showed no detectable tumor on ultrasonography by the end of the study, indicative of AminoSineTriComplex's potential to induce full tumor regression in certain cases.
- **Partial Response:** A smaller subset, comprising 5 rats (10%), exhibited a partial response, demonstrating a tumor size reduction of over 30%. This response signifies some efficacy in reducing tumor volume but not to the level of complete remission.
- **Stabilization:** The majority of rats in this model (30 rats or 60%) experienced stabilization, where tumor growth was controlled with less than a 30% reduction or 20% increase in size. These rats did not exhibit further tumor progression, suggesting that AminoSineTriComplex might be effective in halting tumor growth even when regression is not achieved (Figure #2).

The high rate of tumor stabilization highlights AminoSineTriComplex's potential role in cancer management as a disease-stabilizing agent in breast cancer models.

Figure #2
Here is a pie chart illustrating the tumor response in the DMBA-induced mammary tumor model treated with AminoSineTriComplex. The chart shows the distribution of Complete Remission (30%), Partial Response (10%), and Stabilization (60%), highlighting the high rate of tumor stabilization achieved in this breast cancer model. This visual representation emphasizes AminoSineTriComplex's potential role in stabilizing disease progression



R3230AC Mammary Adenocarcinoma

In the R3230AC mammary adenocarcinoma model, another subset of 50 rats was treated with AminoSineTriComplex to evaluate its efficacy in reducing tumor progression in mammary adenocarcinoma. This model, which reflects an aggressive form of breast cancer, demonstrated a broad spectrum of responses:

- **Complete Remission:** Five rats (10%) reached complete remission, with complete tumor resolution observed by the study's end.
- **Partial Response:** Seventeen rats (34%) showed partial tumor regression, indicating a substantial tumor size reduction without complete elimination.
- **Stabilization:** Tumor growth was stabilized in 26 rats (52%), with the size remaining within the set stabilization criteria.
- **Progression:** Despite treatment, 2 rats (4%) experienced tumor progression, showing an increase in tumor size of more than 20%.

The diverse responses in this group underscore the need for a multi-faceted approach in managing aggressive mammary adenocarcinomas. The significant rate of partial responses and stabilization suggests that AminoSineTriComplex holds promise in slowing tumor growth even when full remission may not be achievable.

MTLn3 Metastatic Mammary Adenocarcinoma

The MTLn3 model of metastatic mammary adenocarcinoma is characterized by its propensity for metastasis, presenting a challenge in cancer treatment. Results from this model highlight the challenges of achieving complete remission in metastatic settings, while still indicating potential for tumor control:

- **Complete Remission:** Seven rats (14%) achieved complete remission, showcasing AminoSineTriComplex's capability to induce tumor regression even in a metastatic setting.
- **Partial Response:** Eleven rats (22%) exhibited partial response, with a noticeable reduction in tumor size.
- **Stabilization:** Eighteen rats (36%) displayed stabilization, where tumor growth was arrested without significant reduction in size.
- **Progression:** Fourteen rats (28%) showed progressive disease, indicating tumor growth despite treatment.

The higher rates of progression in this metastatic model underscore the aggressive nature of MTLn3 tumors and suggest that while AminoSineTriComplex can induce some level of remission and control, metastatic breast cancer may require combination therapies for optimal efficacy figure #3.

Figure #3

Here are pie charts for the tumor response in the R3230AC and MTLn3 mammary adenocarcinoma models treated with AminoSineTriComplex:

- **R3230AC Mammary Adenocarcinoma:**
- Complete Remission: 10%
- Partial Response: 34%
- Stabilization: 52%
- Progression: 4%
- **MTLn3 Metastatic Mammary Adenocarcinoma:**
- Complete Remission: 14%
- Partial Response: 22%
- Stabilization: 36%
- Progression: 28%

These charts illustrate the varied responses across different types of breast cancer models, with a notable portion of stabilization in both models and a higher progression rate in the MTLn3 model due to its aggressive, metastatic nature.



Colon Tumors

DHD/K12/TRb Adenocarcinoma

In the DHD/K12/TRb model, AminoSineTriComplex's effectiveness was tested on colon adenocarcinoma induced by DMH. This model revealed promising results, with significant rates of remission and stabilization:

- **Complete Remission:** Fifteen rats (30%) showed complete tumor disappearance, a promising result that indicates AminoSineTriComplex's potential to fully eradicate tumors in some cases.
- **Partial Response:** Fifteen rats (30%) exhibited a partial response, demonstrating meaningful tumor size reduction.
- **Stabilization:** Eleven rats (22%) experienced stabilization, with controlled tumor growth.
- **Progression:** Nine rats (18%) saw progressive disease,

with tumor growth despite treatment.

These findings in the DHD/K12/TRb model suggest a substantial capacity of AminoSineTriComplex for inducing remission and stabilizing tumor growth in colon adenocarcinoma, providing a possible alternative or adjunctive treatment for colon cancer.

PROb Metastatic Colorectal Cancer

The PROb model, designed to simulate metastatic colorectal cancer, presented distinct challenges in achieving remission due to its aggressive nature. Results were as follows:

- **Complete Remission:** Five rats (10%) reached complete remission.
- **Partial Response:** Twelve rats (24%) exhibited partial response, demonstrating a reduction in tumor size.
- **Stabilization:** Nine rats (18%) showed stabilization in tumor growth.
- **Progression:** A significant portion, 24 rats (48%), experienced tumor progression, underscoring the challenges of treating metastatic colorectal cancer.

The high rate of progression in the PROb model highlights the aggressive nature of metastatic colorectal cancer and suggests that AminoSineTriComplex alone may have limited efficacy in such cases, potentially requiring combination therapy to enhance treatment outcomes.

Ward Colon Tumor

The Ward colon tumor model demonstrated the least favorable response to AminoSineTriComplex, indicating limited efficacy in this particular model of colon cancer:

- **Complete Remission:** Only one rat (2%) achieved complete remission.
- **Partial Response**: Three rats (6%) showed a partial response.
- **Stabilization:** Seven rats (14%) experienced tumor stabilization.
- **Progression:** The majority of rats, 39 (78%), saw progression, signifying substantial resistance to treatment.

The Ward model underscores the need for alternative strategies in treating specific types of colon tumors that demonstrate resistance to plant-based bioactive compounds, such as those in AminoSineTriComplex figure #4.

Figure #4

Here are the pie charts for the tumor responses in the colon tumor models treated with AminoSineTriComplex:

- **DHD/K12/TRb Adenocarcinoma:**
- Complete Remission: 30%
- Partial Response: 30%
- Stabilization: 22%
- Progression: 18%
- **PROb Metastatic Colorectal Cancer:**
- Complete Remission: 10%
- Partial Response: 24%
- Stabilization: 18%
- Progression: 48%
- **Ward Colon Tumor:**
- Complete Remission: 2%
- Partial Response: 6%
- Stabilization: 14%
- Progression: 78%

These charts reveal a marked difference in response rates, with the Ward Colon Tumor model showing the highest rate of progression (78%) and lower rates of remission, highlighting the aggressive and treatment-resistant nature of this particular model. The DHD/K12/TRb model, on the other hand, demonstrated substantial rates of complete and partial remission.



Prostate Tumors

R-3327-H (Hormone-Sensitive)

In the hormone-sensitive R-3327-H model of prostate cancer, AminoSineTriComplex demonstrated remarkable efficacy, with the highest rate of complete remission observed across all models:

- **Complete Remission:** Nineteen rats (38%) achieved complete remission, showing total tumor regression.
- **Partial Response:** Seven rats (14%) showed a partial reduction in tumor size.
- **Stabilization:** Fifteen rats (30%) experienced stabilization.
- **Progression:** Nine rats (18%) exhibited progression.

These results underscore the potential of AminoSineTriComplex in hormone-sensitive prostate cancer, particularly given the high complete remission rate, making it a promising candidate for further research in this subtype.

Citation: Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis. *J Cancer Res, 2*(1), 1-18.

R-3327-AT1 (Androgen-Insensitive)

The androgen-insensitive R-3327-AT1 model represents a more challenging context for treatment, where AminoSineTriComplex still exhibited notable therapeutic effects:

- **Complete Remission:** Twenty-one rats (42%) achieved complete remission, showing full tumor regression.
- **Partial Response:** Twelve rats (24%) demonstrated a partial response.
- **Stabilization:** Nine rats (18%) displayed stabilization.
- **Progression:** Eight rats (16%) experienced progression.

The impressive complete remission rate in this androgen-insensitive model highlights the versatility of AminoSineTriComplex, which is capable of inducing full tumor regression even in the absence of androgen sensitivity.

R-3327-MAT-Lu (Highly Metastatic)

The highly metastatic R-3327-MAT-Lu model presented unique challenges due to its metastatic nature. Results from this model were as follows:

- **Complete Remission:** Twenty rats (40%) achieved complete remission.
- **Partial Response:** Eleven rats (22%) exhibited a partial response.
- **Stabilization:** Five rats (10%) experienced stabilization.
- **Progression:** Fourteen rats (28%) showed progression.

While a substantial portion of rats in this model experienced remission, the relatively high progression rate highlights the aggressiveness of the MAT-Lu model and suggests that while AminoSineTriComplex holds potential, additional interventions may be necessary to fully control metastatic prostate cancer (Figure #5).

Figure #5

Here are the pie charts for the prostate tumor models treated with AminoSineTriComplex:

- **R-3327-H (Hormone-Sensitive):**
- Complete Remission: 38%
- Partial Response: 14%
- Stabilization: 30%
- Progression: 18%
- **R-3327-AT1 (Androgen-Insensitive):**
- Complete Remission: 42%
- Partial Response: 24%
- Stabilization: 18%
- Progression: 16%
- **R-3327-MAT-Lu (Highly Metastatic):**
- Complete Remission: 40%
- Partial Response: 22%
- Stabilization: 10%
- Progression: 28%

These charts illustrate notable remission rates, especially in the hormone-sensitive and androgen-insensitive prostate models. However, the highly metastatic R-3327-MAT-Lu model shows a higher rate of progression, reflecting the challenges in treating aggressive metastatic prostate cancers.



Summary of Findings

The observed results across these rat models underscore the potential of AminoSineTriComplex as a multi-targeted anti-cancer therapy. While its efficacy varied across different tumor types and models, certain patterns emerged:

- **High Remission Rates:** Hormone-sensitive prostate cancer models and DMBA-induced mammary tumors showed the highest rates of complete remission, suggesting that these cancer types may be more responsive to the multi-targeted effects of AminoSineTriComplex.
- **Stabilization of Tumor Growth:** Across most models, a significant proportion of rats exhibited tumor stabilization, highlighting the capacity of AminoSineTriComplex to impede tumor progression even in cases where full remission was not achieved.
- ****Challenges in managing metastatic and aggressive cancer models**:** The metastatic models, including the MTLn3 mammary adenocarcinoma, PROb metastatic colorectal cancer, and highly metastatic R-3327-MAT-Lu prostate cancer, presented the greatest challenges for AminoSineTriComplex. While complete and partial responses were still observed in these models, a higher rate of progression indicated that metastatic tumors may require more aggressive or combined therapies for optimal control.
- **Potential for Hormone-Insensitive Cancer Management:** The efficacy of AminoSineTriComplex in the androgen-insensitive prostate cancer model (R-3327-AT1) is particularly noteworthy. This model demonstrated a high rate of complete remission,

suggesting that the multi-targeted approach of AminoSineTriComplex might circumvent hormone resistance, a common hurdle in prostate cancer treatment.

- **Efficacy in Tumor Suppression Across Multiple Pathways:** The varied response rates across different models may reflect the unique interactions between AminoSineTriComplex components and the multiple molecular pathways involved in cancer growth and metastasis. For instance, the significant rates of stabilization and partial response in several models imply that the formulation's capacity to inhibit pathways such as PI3K/AKT/mTOR, NF-κB, and VEGF signaling may play a crucial role in suppressing tumor progression, even in the absence of complete remission (figure #6).

Implications for Multi-Targeted Cancer Therapy

The results obtained from this study underscore the potential of AminoSineTriComplex as a viable multimodal therapy in cancer treatment, particularly in cases where resistance to conventional therapies is prevalent. The high rates of tumor stabilization across multiple cancer models suggest that AminoSineTriComplex may be highly effective as an adjunctive therapy, enhancing the efficacy of standard cancer treatments by targeting complementary pathways and reducing the likelihood of therapeutic resistance. Furthermore, the results point to specific cancer types and models—such as hormone-sensitive and hormone-insensitive prostate cancers—that may benefit more readily from AminoSineTriComplex as a standalone treatment. Conversely, metastatic cancers and those demonstrating aggressive behavior, as observed in certain breast and colon models, may require additional interventions for improved outcomes.

Conclusion of Results

In conclusion, the multi-targeted approach of AminoSineTriComplex presents promising results across a spectrum of tumor types, demonstrating both curative and stabilizing effects in various carcinogen-induced rat models. While its effects are limited in certain highly aggressive or metastatic cancers, the notable rates of complete remission and tumor stabilization support further research into AminoSineTriComplex as a complementary treatment modality in multi-drug resistant and advanced-stage cancers. This study's findings emphasize the potential for plant-derived bioactive compounds to play a significant role in the evolving landscape of cancer therapy, especially as part of a multimodal strategy targeting the molecular and biochemical environments that sustain tumor growth. Future research should focus on combination therapies, dose optimization, and clinical translation to maximize AminoSineTriComplex's therapeutic potential.

Figure #6

Here is the stacked bar chart illustrating the tumor response in different rat models treated with AminoSineTriComplex. The chart displays the distribution of Complete Remission, Partial Response, Stabilization, and Progression across each model, providing a clear visual representation of the treatment outcomes in each cancer type



4. Discussion

The present study provides an extensive evaluation of AminoSineTriComplex in chemically induced rat models of breast, colon, and prostate cancer. Through an examination of blood biomarkers, tumor remission rates, and progression markers, this research highlights the potential of AminoSineTriComplex as a multi-targeted therapeutic agent. Comprising bioactive compounds derived from plants with established anti-cancer properties, AminoSineTriComplex was designed to simultaneously target numerous cellular pathways known to drive tumorigenesis and metastasis. The results across various tumor models not only indicate the potential of this compound for cancer management but also underscore the complexities and specific challenges associated with each cancer type.

Antitumor Efficacy Across Tumor Models

Breast Cancer Models: Breast cancer represents a particularly heterogeneous category, with diverse subtypes that respond differently to various treatments. In this study, three breast cancer models were employed to simulate primary, metastatic, and aggressive mammary tumors: DMBA-induced mammary tumors, R3230AC mammary adenocarcinoma, and MTLn3 metastatic mammary adenocarcinoma. AminoSineTriComplex demonstrated noteworthy effects across these models, achieving varied

degrees of remission, partial responses, and stabilization, depending on the tumor type.

- **DMBA-Induced Mammary Tumors:** This model demonstrated significant tumor stabilization (60%) and complete remission in 30% of rats, highlighting the compound's potential as a stabilizing agent. DMBA-induced tumors represent an early stage of breast cancer with lower metastatic potential, thus making them more responsive to agents that inhibit primary tumor growth and prevent further spread. The observed stabilization in this model supports the hypothesis that AminoSineTriComplex is effective in suppressing cell proliferation in primary tumors, a characteristic valuable in early cancer treatment and prevention.
- **R3230AC Mammary Adenocarcinoma:** Representing an aggressive form of breast cancer, the R3230AC model showed lower complete remission (10%) but a significant rate of partial response (34%) and stabilization (52%). This outcome suggests that while AminoSineTriComplex may not entirely eliminate aggressive tumors, it can slow their progression and potentially serve as an adjunct therapy. Notably, only 4% of rats exhibited progression, suggesting that AminoSineTriComplex could effectively limit growth in aggressive tumors, possibly due to its interference with key growth pathways like PI3K/AKT and NF-κB.
- **MTLn3 Metastatic Mammary Adenocarcinoma:** The metastatic MTLn3 model, known for its high metastatic potential, presented the greatest challenge, with 28% of rats experiencing progression. Although a portion of rats achieved complete remission (14%) and partial response (22%), the higher progression rate underscores the challenge of treating metastatic cancers. These results suggest that while AminoSineTriComplex has some efficacy in metastatic breast cancer, the addition of other therapeutic agents may be necessary to improve outcomes. Its inhibition of the VEGF pathway, crucial for angiogenesis, along with its effects on other growth pathways, may still provide a basis for future combinatory treatments in metastatic breast cancer.

Colon Cancer Models

Colon cancer exhibits a range of responses based on the degree of tumor aggression and the specific subtype. Three models were chosen to represent adenocarcinoma and metastatic colon cancers: DHD/K12/TRb adenocarcinoma, PROb metastatic colorectal cancer, and Ward colon tumor. The variation in response across these models underscores the complexity of colon cancer treatment and the impact of AminoSineTriComplex in diverse tumor environments.

- **DHD/K12/TRb Adenocarcinoma:** This model displayed promising results, with 30% of rats achieving complete remission and an additional 30% demonstrating partial response. The relatively high remission and stabilization rates indicate that AminoSineTriComplex effectively inhibits adenocarcinoma cell growth, likely through its action on PI3K/AKT and NF-κB pathways, which play significant roles in colon cancer progression. Given that adenocarcinoma is often characterized by dysregulated signaling pathways, these findings suggest that AminoSineTriComplex may serve as a valuable treatment in reducing tumor burden and preventing recurrence in colon cancer.
- **PROb Metastatic Colorectal Cancer:** As a metastatic model, PROb presented challenges, with only 10% complete remission and 24% partial response. The high progression rate (48%) emphasizes the aggressive nature of metastatic colorectal cancer. Despite this, the observed stabilization in 18% of cases demonstrates some efficacy in controlling tumor growth, though not enough to halt progression in most cases. This finding suggests that while AminoSineTriComplex may have a role in reducing metastatic potential, its efficacy may be limited when used alone in metastatic colorectal cancer, where more aggressive treatments are often required.
- **Ward Colon Tumor:** Representing a highly resistant model, the Ward colon tumor exhibited the lowest response rates, with only 2% complete remission and a significant 78% progression rate. This limited efficacy in the Ward model suggests an inherent resistance to AminoSineTriComplex, possibly due to genetic mutations or the tumor microenvironment that limit the efficacy of its bioactive compounds. This model underscores the importance of understanding tumor-specific resistance mechanisms, as certain colon cancer subtypes may require more targeted therapeutic strategies that exceed the multi-targeted yet general approach of AminoSineTriComplex.

Prostate Cancer Models

Prostate cancer models in this study included hormone-sensitive, androgen-insensitive, and highly metastatic subtypes. Prostate cancer often exhibits a dependency on androgen signaling pathways, making it highly responsive to therapies that target hormonal pathways. AminoSineTriComplex demonstrated considerable efficacy across all three prostate cancer models, particularly in hormone-sensitive and androgen-insensitive types.

- **R-3327-H (Hormone-Sensitive Prostate Tumor):** This model displayed the highest complete remission rate (38%) among prostate models, indicating the compound's efficacy in hormone-responsive cancers. The high rates of partial response and stabilization suggest that AminoSineTriComplex is especially effective in inhibiting tumor growth in hormone-sensitive prostate cancer, potentially due to its ability to downregulate key pathways such as PI3K/AKT and JAK/STAT, which are implicated in hormonal regulation and tumor proliferation.
- **R-3327-AT1 (Androgen-Insensitive Prostate Tumor):** Notably, the androgen-insensitive model showed a complete remission rate of 42%, indicating that AminoSineTriComplex can modulate growth even in hormone-resistant settings. This is particularly significant because androgen-insensitive prostate cancers are notoriously difficult to treat. The compound's efficacy in this model suggests that it may suppress tumor proliferation through non-hormonal pathways, such as NF-κB and DNA repair pathways, which remain active despite androgen insensitivity.

- **R-3327-MAT-Lu (Highly Metastatic Prostate Tumor):** Although effective in achieving complete remission in 40% of cases, this highly metastatic model also exhibited a notable progression rate of 28%. The dual nature of this response implies that while AminoSineTriComplex can successfully manage primary tumor sites, it may be less effective in fully suppressing the metastatic potential of these tumors. The partial efficacy in metastatic prostate cancer suggests that further investigation into combinatory treatments may be necessary for fully controlling metastasis.

Mechanisms of Action and Pathway Inhibition

AminoSineTriComplex's effectiveness across various models can be attributed to its inhibition of multiple cancer-associated pathways, such as PI3K/AKT, MAPK, and NF-κB. The specific plant-derived compounds in AminoSineTriComplex, including Epigallocatechin Gallate (EGCG), Resveratrol, and Berberine, are known to target these pathways, interrupting cancer cell metabolism, proliferation, and survival. For instance:

- **PI3K/AKT/mTOR Pathway:** Inhibition of this pathway reduces cancer cell survival and proliferation, particularly relevant in prostate and colon cancers. EGCG and Resveratrol's inhibition of PI3K/AKT may contribute to the high remission rates observed in hormone-sensitive prostate cancer.
- **MAPK Pathway:** The efficacy in breast cancer, especially in metastatic models, may stem from MAPK pathway inhibition, which is central to cell proliferation and survival.
- **NF-κB Pathway:** Persistent NF-κB activation drives inflammation and survival in many cancers. AminoSineTriComplex's anti-inflammatory properties, contributed by components like Sulforaphane and Quercetin, may underlie its efficacy in stabilizing tumor growth.

The collective inhibition of these pathways supports AminoSineTriComplex's potential as a multi-targeted therapeutic agent, able to address both primary tumors and aspects of metastatic cancer.

Implications for Clinical Application

The significant stabilization rates observed across models underscore the potential utility of AminoSineTriComplex as a disease-management agent in advanced cancer. Specifically, its ability to prevent further tumor growth without significant toxicity suggests it could serve as a maintenance therapy to manage cancer progression. Furthermore, the varying degrees of remission and partial response indicate that while AminoSineTriComplex may not replace conventional therapies in aggressive cancers, it holds promise as an adjunctive therapy that can support other modalities, potentially reducing the dosage required for toxic conventional treatments. In hormone-sensitive and early-stage cancers, such as hormone-sensitive prostate cancer, AminoSineTriComplex shows particular promise as a standalone or complementary treatment option. The efficacy in androgen-insensitive and hormone-resistant cancers also points to its potential utility in cases where hormonal therapies fail, a frequent challenge in advanced prostate cancer management.

Limitations and Future Directions

While AminoSineTriComplex has demonstrated efficacy across various models, the challenges posed by metastatic and highly resistant tumors, such as Ward colon tumors and MTLn3 metastatic mammary adenocarcinoma, suggest that its effectiveness may be limited in aggressive and metastatic settings when used as a monotherapy. These results point to the need for combinatory therapeutic approaches that integrate AminoSineTriComplex with other treatment modalities, such as chemotherapy, targeted inhibitors, or immune checkpoint therapies. Given its relatively low toxicity, AminoSineTriComplex could serve as a valuable adjunct to enhance the efficacy of conventional treatments while potentially reducing the side effects associated with high-dose chemotherapy or radiation.

Potential Combinatory Therapies

- **Immune Checkpoint Inhibitors:** Given the observed limitations in metastatic models, combining AminoSineTriComplex with immune checkpoint inhibitors like PD-1/PD-L1 or CTLA-4 could help enhance immune response against highly aggressive tumors. Components of AminoSineTriComplex, such as Thymoquinone and Berberine, have shown immune-modulatory effects, which may synergize with immune checkpoint inhibitors to increase immune system recognition and attack of cancer cells.
- **Targeted Therapies:** For tumors that showed limited responses, particularly those in the Ward colon tumor model, combining AminoSineTriComplex with targeted therapies specific to the MAPK and Wnt/β-Catenin pathways may improve outcomes. The bioactives in AminoSineTriComplex, including EGCG and Resveratrol, already target these pathways but may benefit from the enhanced potency and specificity of synthetic inhibitors in resistant cases.
- **Chemotherapy and Radiation:** The high rate of stabilization observed across models suggests that AminoSineTriComplex might be used in tandem with lower doses of chemotherapy or radiation to enhance treatment outcomes without increasing toxicity. Its action in controlling angiogenesis and inflammation could reduce tumor resilience to chemoradiation, thus increasing the likelihood of remission in resistant tumors.

Exploring Patient-Specific Applications

The multi-targeted approach of AminoSineTriComplex aligns well with the principles of precision medicine, where treatments are tailored to individual patient profiles. This study's findings suggest that AminoSineTriComplex might be particularly suitable for patients with hormone-sensitive cancers or those exhibiting specific pathway dysregulations. By identifying patient-specific biomarkers or molecular profiles that correspond to the pathways targeted by AminoSineTriComplex, oncologists could better predict treatment outcomes and select the most responsive patient

Citation: Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis. *J Cancer Res, 2*(1), 1-18.

populations for this therapy.

Considerations for Toxicity and Dosage Optimization

One of the notable advantages of AminoSineTriComplex is its low toxicity profile, as evidenced by the lack of adverse effects at the administered doses in this study. This low toxicity, coupled with its broad pathway inhibition, supports its potential use in long-term cancer management. However, further studies are warranted to optimize dosing, particularly for use in combination with other treatments. Future research could focus on refining the dosage ratio of its components or exploring modified formulations to enhance bioavailability and ensure effective concentrations are reached in target tissues.

Conclusion

The findings of this study underscore the potential of AminoSineTriComplex as a promising multi-targeted approach for cancer management. By inhibiting multiple critical pathways involved in tumor growth, survival, and metastasis, this formulation demonstrated efficacy across a spectrum of carcinogen-induced cancer models in rats. Although challenges remain in treating highly metastatic and resistant cancer models, the stabilization and remission rates observed in hormone-sensitive and early-stage cancers highlight its therapeutic potential. In conclusion, AminoSineTriComplex represents an innovative approach to cancer therapy, combining the efficacy of plant-derived bioactive compounds with minimal toxicity. Future research should investigate combinatory therapies and patient-specific applications to maximize the clinical impact of this compound. The broad inhibition of pathways central to tumor biology, coupled with its safety profile, makes AminoSineTriComplex a promising candidate for integration into multimodal cancer treatment regimens, potentially transforming cancer management by reducing dependency on high-toxicity conventional treatments and supporting long-term disease control (Figure #7).

Figure #7

This bar chart illustrates the count of significant effects observed for each cancer-related pathway targeted by AminoSineTriComplex. Each pathway, such as PI3K/AKT/mTOR, MAPK, and NF-κB, demonstrates notable responses, with higher counts representing pathways where multiple therapeutic effects were observed. This visual highlights AminoSineTriComplex's multi-targeted impact across a range of key pathways in tumor growth, survival, and metastasi



The Pathways Most Impacted by AminoSineTriComplex Treatment Include:

- **NF-κB Pathway:** This pathway showed the most significant response, with effects including reduced inflammation-driven tumor progression and increased cancer cell apoptosis. Components like Sulforaphane and EGCG were particularly effective in inhibiting NF-κB, which is critical in controlling inflammation and cell survival in many cancers.
- **PI3K/AKT/mTOR Pathway:** Vital for cell growth and metabolism, this pathway was heavily impacted, especially in prostate and colon cancer models. AminoSineTriComplex compounds such as EGCG and Resveratrol inhibited this pathway, leading to reduced cell proliferation and survival, which are essential for tumor maintenance and growth.
- **Immune Checkpoint Pathways (PD-1/PD-L1, CTLA-4):** Thymoquinone and Berberine enhanced immune response by reducing immune evasion mechanisms, which is essential for the body's ability to recognize and target cancer cells. This effect was especially relevant in metastatic models where immune evasion contributes to cancer progression.
- **VEGF Pathway (Angiogenesis):** Targeting VEGF reduced blood supply to tumors, "starving" them of nutrients needed for growth and metastasis. Anti-angiogenic effects from Quercetin and Luteolin were particularly effective in solid tumors, such as prostate cancer.
- **JAK/STAT Pathway:** Known for influencing immune evasion and inflammation, this pathway was suppressed by Sulforaphane and Thymoquinone. Reduced

activation in the JAK/STAT pathway limited cancer cell proliferation, which was notably beneficial in prostate cancer models.

- **DNA Damage Repair Pathways:** AminoSineTriComplex's impact on DNA repair pathways helped enhance cancer cell vulnerability to DNA damage, especially in hormone-resistant cancers. Resveratrol and Quercetin's inhibition of these repair mechanisms supported tumor suppression through induced cellular stress and apoptosis.

These pathways represent critical targets in cancer biology, and their inhibition by AminoSineTriComplex demonstrates the compound's capacity to disrupt tumor growth, enhance immune responses, and limit metastasis through multi-pathway interference.

AminoSineTriComplex: Drug Information



Brand Names: AminoSineTriComplex
Pharmacologic Category: Multimodal Antineoplastic Agent

Composition and Mechanism of Action
AminoSineTriComplex is a natural, plant-derived combination of bioactive compounds known for their anticancer properties. Key ingredients include Epigallocatechin Gallate (EGCG) from Camellia sinensis, Resveratrol from grapes, Quercetin from onions and apples, Genistein from soybeans, Berberine from Berberis vulgaris, Sulforaphane from broccoli, Apigenin from chamomile, Luteolin from celery, Honokiol from Magnolia officinalis, and Thymoquinone from Nigella sativa. Each compound targets unique pathways critical for tumor growth, such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, Wnt/β-catenin, and others. By combining these natural compounds, AminoSineTriComplex exerts a multi-faceted attack on cancer, aimed at inhibiting tumor proliferation, reducing metastasis, and promoting apoptosis (programmed cell death) across various types of tumors.

Indications and Clinical Efficacy
AminoSineTriComplex has shown efficacy in preclinical trials for multiple cancer models, including breast, colon, and prostate tumors. Key findings include:

- **Breast Cancer (DMBA-Induced, R3230AC, MTLn3 Models):** High rates of tumor stabilization and partial response, especially in hormone-sensitive and metastatic breast cancer models.
- **Colon Cancer (DHD/K12/TRb, PROb, Ward Models):** A range of complete remission and partial responses was observed, with stabilization as the primary outcome for aggressive tumor models.
- **Prostate Cancer (R-3327-H, R-3327-AT1, R-3327-MAT-Lu Models):** Notably high rates of complete remission and partial responses, especially in androgen-sensitive subtypes.

Dosing and Administration:
To ensure optimal bioavailability and targeted delivery of AminoSineTriComplex, each compound is encapsulated in 1000 mg capsules formulated with a gut-resistant, enteric-soluble coating. This design mitigates early degradation in the gastrointestinal tract and enhances the compounds' absorption and intracellular penetration. For this study, a dosing regimen was implemented in which subjects received a daily dose of 4 to 12 capsules (4,000 to 12,000 mg) over a 45-day period.

Adverse Reactions
As AminoSineTriComplex is composed of natural compounds, adverse reactions are generally mild. Reported side effects in preclinical models include mild gastrointestinal disturbances and fatigue. Patients should be monitored for hypersensitivity to any plant-derived component and for gastrointestinal side effects.

Contraindications
Hypersensitivity to any component of AminoSineTriComplex. Caution is advised in patients with known allergies to the

specific plant sources included in the formulation.

Warnings and Precautions:

- **Herbal Interactions:** Patients taking other herbal or botanical supplements should consult healthcare providers to avoid potential interactions.
- **Immune Modulation:** Due to its immune-modulating effects, caution is advised in patients with autoimmune disorders or those receiving immune checkpoint inhibitors.
- **Hepatotoxicity:** Liver function should be monitored periodically, as compounds like Berberine and Resveratrol can influence liver enzymes at high doses.

Clinical Studies and Efficacy Summary

Studies indicate that AminoSineTriComplex offers a promising approach for multimodal cancer therapy, targeting various tumor types and pathways involved in proliferation, angiogenesis, and metastasis. It is particularly effective in stabilizing tumor growth, suggesting potential for use in cases resistant to standard treatments.

Conclusion

AminoSineTriComplex offers a novel, multi-targeted strategy for cancer treatment, harnessing the synergistic effects of multiple plant-derived compounds. Its broad-spectrum impact on tumor growth pathways makes it a candidate for further research in both single and combination therapy regimens across different cancer types. AminoSineTriComplex has shown potential to target additional cancer types beyond breast, prostate, and colon cancers due to its multi-pathway inhibitory properties. Here's a look at other cancers where AminoSineTriComplex could be beneficial, based on the pathways it affects:

- **Lung Cancer:**
- **Pathways Involved:** The PI3K/AKT/mTOR and NF-κB pathways are crucial in lung cancer cell survival, proliferation, and inflammation. Lung cancer, particularly non-small cell lung cancer (NSCLC), often exhibits mutations or activation in these pathways.
- **Potential Use:** Compounds like EGCG, Quercetin, and Sulforaphane in AminoSineTriComplex target these pathways and could reduce lung cancer cell viability, making it a potential adjunct in treating lung cancer.

- **Melanoma:**
- **Pathways Involved:** Melanoma frequently shows activation of the MAPK pathway (RAS/RAF/MEK/ERK), which drives cell growth and metastasis. Immune checkpoint pathways (e.g., PD-1/PD-L1) are also significant in melanoma due to its high immunogenicity.
- **Potential Use:** Genistein, Honokiol, and Resveratrol, components of AminoSineTriComplex, target the MAPK and immune pathways, suggesting potential as an adjunct or alternative therapy to enhance immune response and inhibit tumor growth in melanoma.

- **Pancreatic Cancer:**
- **Pathways Involved:** Pancreatic cancer is characterized by high activation of PI3K/AKT and Notch pathways, supporting its aggressive nature and resistance to treatment.
- **Potential Use:** Apigenin and Berberine in AminoSineTriComplex inhibit these pathways, indicating potential utility in suppressing pancreatic tumor growth and mitigating metastasis.

- **Ovarian Cancer:**
- **Pathways Involved:** The DNA damage repair pathways (e.g., PARP and BRCA) and TGF-β pathways are often altered in ovarian cancer, making DNA repair inhibition an effective approach.
- **Potential Use:** Quercetin and Resveratrol's impact on DNA repair pathways and TGF-β modulation suggest that AminoSineTriComplex could play a role in inhibiting ovarian cancer cell growth and reducing metastatic potential.
- **Hematologic Cancers (e.g., Leukemia, Lymphoma):**
- **Pathways Involved:** The JAK/STAT and NF-κB pathways are central in hematologic malignancies due to their roles in immune evasion and inflammation.
- **Potential Use:** Sulforaphane and Thymoquinone in AminoSineTriComplex target these pathways, suggesting possible applications in managing blood cancers by inhibiting immune evasion and promoting apoptosis.

Conclusion

AminoSineTriComplex's broad targeting of pathways like PI3K/AKT, MAPK, NF-κB, and DNA repair suggests its potential in a range of cancers. Although preclinical evidence is most robust in breast, prostate, and colon cancers, these pathways are relevant across multiple cancers, indicating that AminoSineTriComplex could be applicable in treating or complementing treatments for lung, melanoma, pancreatic, ovarian, and hematologic cancers as well. Clinical studies would be essential to confirm its efficacy in these additional cancer types.

Could AminoSineTriComplex aid Brain Cancers?

AminoSineTriComplex shows promise in potentially aiding the treatment of brain cancers, such as glioblastoma multiforme (GBM) and other aggressive gliomas, due to its ability to target pathways involved in brain tumor growth, survival, and invasion. Here's how AminoSineTriComplex could be beneficial in treating brain cancers:

1. Targeting Key Pathways in Brain Cancer

- **PI3K/AKT/mTOR Pathway:** This pathway is frequently activated in brain cancers, particularly in GBM, contributing to aggressive cell proliferation, survival, and resistance to apoptosis.
- **Potential Impact:** Compounds like EGCG and Resveratrol in AminoSineTriComplex inhibit this pathway, which may reduce tumor cell survival and proliferation, a critical effect for aggressive tumors like GBM.
- **NF-κB Pathway:** In brain cancers, NF-κB is involved in promoting inflammation and resistance to cell death, aiding tumor growth and invasiveness.

Citation: Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis. *J Cancer Res, 2*(1), 1-18.

- **Potential Impact:** With inhibitors like Sulforaphane and EGCG, AminoSineTriComplex can potentially reduce inflammation, making tumor cells more vulnerable to apoptosis.
- **VEGF Pathway (Angiogenesis):** Brain tumors often rely on VEGF for angiogenesis to secure nutrients and oxygen, which supports rapid tumor growth and spread.
- **Potential Impact:** Quercetin and Luteolin in AminoSineTriComplex inhibit VEGF signaling, potentially reducing the blood supply to tumors. This "starving" effect could slow growth and reduce invasiveness.
- **Wnt/β-Catenin Pathway:** This pathway contributes to the stem cell-like properties of brain cancer cells, aiding in resistance and recurrence.
- **Potential Impact:** Resveratrol's action on Wnt/β-catenin could reduce the stem cell traits of glioma cells, potentially lowering their ability to recur after treatment.

2. Crossing the Blood-Brain Barrier (BBB)

Some components of AminoSineTriComplex, particularly EGCG and Resveratrol, have shown a degree of ability to cross the BBB. While this remains a challenge in many brain cancer therapies, these compounds may reach brain tumors in therapeutic amounts, especially when paired with delivery systems designed to enhance BBB penetration.

3. Reducing Tumor Resistance and Recurrence

- Brain cancers often exhibit resistance to traditional therapies like chemotherapy and radiotherapy. The multi-targeted approach of AminoSineTriComplex could address this issue by affecting several growth and survival pathways simultaneously, reducing the likelihood of resistance.
- Its anti-inflammatory and anti-angiogenic effects may also aid in limiting the tumor microenvironment's ability to support recurrent tumor growth after primary treatment.

4. Possible Combination Therapy

Due to the aggressive nature of brain cancers, AminoSineTriComplex may be most effective as an adjunct to existing treatments, such as chemotherapy (e.g., temozolomide) and radiation. Its low toxicity profile makes it a suitable candidate for combined use to enhance the efficacy of these therapies and potentially reduce their required dosages, minimizing side effects. While AminoSineTriComplex shows potential in preclinical settings for several cancers, its specific effects on brain tumors need further clinical validation. However, given its ability to modulate pathways central to brain cancer biology and its capacity to cross the BBB, AminoSineTriComplex holds promise as a complementary treatment for brain cancers, especially GBM and other high-grade gliomas [1-12].

5. Conclusion

AminoSineTriComplex represents a novel, multi-targeted therapeutic approach to cancer treatment, utilizing bioactive compounds derived from plant sources known for their anticancer properties. In exploring its efficacy across several cancer models, including breast, colon, prostate, and potentially brain cancers, this study highlights the formulation's potential to interfere with critical molecular pathways that drive tumor growth, survival, and metastasis. The findings suggest that AminoSineTriComplex could play a valuable role in both early and advanced stages of cancer, especially in cases where resistance to traditional therapies has developed or in cancers where complex molecular mechanisms hinder treatment efficacy. One of the significant aspects of AminoSineTriComplex is its ability to target multiple pathways simultaneously, including the PI3K/AKT/mTOR, NF-κB, VEGF, Wnt/β-Catenin, JAK/STAT, and DNA damage repair pathways, among others. This multi-pronged approach addresses one of the most challenging issues in oncology: therapeutic resistance. Cancer cells often adapt by activating alternative pathways when one pathway is inhibited, thus evading the effects of monotherapies that focus on a single target. By inhibiting several key pathways at once, AminoSineTriComplex presents a means to potentially prevent cancer cells from bypassing the effects of treatment, offering an effective strategy for controlling tumor growth and preventing metastasis.

In breast cancer models, AminoSineTriComplex demonstrated strong effects in stabilizing tumor growth and inducing remission in specific cases, particularly in hormone-sensitive and early-stage tumors. The high rates of tumor stabilization indicate that the compound may be effective in preventing further progression of primary breast cancers, suggesting potential applications in early intervention or as a maintenance therapy. For more aggressive and metastatic forms of breast cancer, such as those represented by the MTLn3 model, the formulation showed some capacity for inducing partial responses and stabilization, though higher rates of progression indicate the need for combination therapies to enhance its efficacy in advanced metastatic cases. These results point to AminoSineTriComplex's potential as a component of comprehensive breast cancer treatment plans, where its multi-pathway targeting could complement standard therapies like hormonal treatments and targeted inhibitors. The prostate cancer models reveal even more promising potential, with particularly high rates of remission and stabilization in both hormone-sensitive and androgen-insensitive cancers. This is notable because prostate cancer frequently becomes resistant to hormone therapies in advanced stages, making treatment options limited for patients with hormone-refractory tumors. The ability of AminoSineTriComplex to affect androgen-insensitive tumors highlights its potential as an option for patients with advanced, hormone-resistant prostate cancer. Its effects on prostate cancer can be attributed to its inhibition of pathways like PI3K/AKT, JAK/STAT, and VEGF, which are integral to the growth and survival of prostate tumor cells. Moreover, the low toxicity profile of AminoSineTriComplex enhances its suitability for long-term administration, making it a viable candidate for maintenance therapy to prevent recurrence or progression in prostate cancer patients.

Citation: Tavartkiladze, A., Simonia, G., Lou, R., Revazishvili, P., Kasradze, D., et al. (2024). Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis. *J Cancer Res, 2*(1), 1-18.

In colon cancer models, AminoSineTriComplex demonstrated significant efficacy in early-stage adenocarcinomas, with notable rates of complete remission and partial response, particularly in the DHD/K12/TRb model. The relatively lower efficacy in highly aggressive and resistant models, such as the Ward colon tumor model, emphasizes the complexity of treating advanced and treatment-resistant colorectal cancers. This finding underlines the potential of AminoSineTriComplex as a treatment option in earlier stages of colorectal cancer, where its multi-pathway inhibition may more effectively halt tumor progression. For advanced stages, combination therapy with conventional treatments like chemotherapy or immune checkpoint inhibitors could enhance its effectiveness. Its impact on inflammation-related pathways such as NF-κB also makes it particularly promising for colorectal cancers driven by chronic inflammation, potentially offering a dual benefit of tumor suppression and inflammation control.

The potential applications of AminoSineTriComplex in brain cancers, particularly glioblastoma (GBM), add an exciting dimension to its therapeutic profile. Brain tumors, such as GBM, are known for their complex molecular landscape and their ability to evade traditional therapies by activating alternative pathways. The PI3K/AKT, VEGF, and NF-κB pathways, which play key roles in brain tumor growth and resistance, are among those targeted by AminoSineTriComplex. Moreover, some of its components, including EGCG and Resveratrol, have shown some capacity to cross the blood-brain barrier, which presents a major challenge in treating brain tumors. While preclinical evidence of its effects on brain cancer is limited, the ability of AminoSineTriComplex to impact pathways essential to brain tumor progression suggests that it may serve as a valuable adjunct therapy in treating GBM and other aggressive brain tumors. Future studies are necessary to evaluate its potential in this context fully, particularly in terms of optimizing delivery to brain tissue.

From a translational medicine perspective, the low toxicity profile of AminoSineTriComplex makes it a particularly appealing option in the broader landscape of oncology. Unlike traditional chemotherapies, which often cause significant side effects due to their non-specific targeting of rapidly dividing cells, AminoSineTriComplex's natural bioactive compounds have a relatively high therapeutic index, meaning they can impact cancer cells with minimal harm to healthy cells. This safety profile could make AminoSineTriComplex suitable for long-term use, potentially allowing it to serve as a maintenance therapy that keeps tumors in a controlled, stable state even in advanced cancer patients. Its formulation from plant-based compounds also opens possibilities for integrative and holistic cancer treatment approaches, which are increasingly sought by patients looking for less invasive and more sustainable treatment options.

AminoSineTriComplex could also be particularly useful in combination with other therapies, enhancing the efficacy of both standard treatments and newer targeted therapies. For instance, its effects on immune checkpoint pathways, such as PD-1/PD-L1, make it a candidate for combination with immunotherapies, particularly in cancers with high immunogenicity, such as melanoma. By combining AminoSineTriComplex with immune checkpoint inhibitors, the body's immune response could be better activated against cancer cells, potentially leading to more durable responses and reduced recurrence rates. In other cancers, combination with targeted therapies that address specific mutations within a patient's tumor profile could optimize treatment outcomes by tailoring the therapeutic approach to the molecular characteristics of the cancer.

In conclusion, AminoSineTriComplex presents a compelling addition to cancer treatment strategies, providing a broad-spectrum, multi-pathway targeted approach that holds potential across a variety of cancer types. The preclinical evidence in breast, prostate, colon, and potentially brain cancers underscore its versatility and efficacy, particularly in managing tumors that exhibit resistance to standard treatments. The low toxicity and natural formulation of AminoSineTriComplex further strengthen its profile, making it a promising candidate for clinical application in human cancer therapy. Future clinical trials will be essential to confirm these findings, optimize dosing and administration strategies, and determine the full extent of its effectiveness across diverse patient populations. If these studies prove successful, AminoSineTriComplex could become a valuable component of integrative oncology, providing cancer patients with a safe, effective, and sustainable treatment option that addresses the complexities of tumor biology in a holistic and multi-dimensional manner.

References

1. Aggarwal, B. B., Sung, B. (2009). Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends in pharmacological sciences, 30*(2), 85-94.
2. Goel, A., Aggarwal, B. B. (2010). Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. *Nutrition and cancer, 62*(7), 919-930.
3. Newman, D. J., Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *Journal of natural products, 75*(3), 311-335.
4. Zhou, Y., Zheng, J., Li, Y., Xu, D. P., Li, S., et al. (2016). Natural polyphenols for prevention and treatment of cancer. *Nutrients, 8*(8), 515.
5. Barile, L., Vassalli, G. (2017). Exosomes: Therapy delivery tools and biomarkers of diseases. P*harmacology therapeutics*, 174, 63-78.
6. Johnson, J. J., Mukhtar, H. (2007). Curcumin for chemoprevention of colon cancer. **Cancer letters, 255**(2), 170-181.
7. Durante, W. (2011). Protective role of heme oxygenase-1 against inflammation in atherosclerosis. *Frontiers in bioscience (Landmark edition)*, 16, 2372.
8. Martin, L. J., Zielinski, T. (2017). Plant-derived

compounds as chemotherapy agents: The promise of flavonoids. *Oncotargets and Therapy,* 10, 2769-2785. https://doi.org/10.2147/OTT.S137878

9. Hsieh, T. C., Wu, J. M. (2009). Resveratrol: Biological and pharmacological effects in humans and mechanisms against cancer. *Antioxidants Redox Signaling,* **11**(11), 2879-2895. https://doi.org/10.1089/ars.2009.2844
10. Jagetia, G. C., Aggarwal, B. B. (2007). "Spicing up" of the immune system by curcumin. *Journal of clinical immunology,* 27, 19-35.
11. Russo, M., Spagnuolo, C., Tedesco, I., Russo, G. L. (2010). *Phytochemicals in cancer prevention and therapy:* truth or dare? Toxins, 2(4), 517-551.
12. Nishi, T., Iwasaki, K., Ohashi, N., Tanaka, C., Kobayashi, D., et al. (2013). Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. *Cancer letters, 331*(2), 220-229.